FTIR studies.

Lornoxicam, is a widely prescribed Non-steroidal anti-inflammatory drug belongs to class II under BCS classification and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It needs enhancement in the dissolution rate in its formulation development.  The main objective was to formulate and evaluate Lornoxicam FDT by incorporating the Lornoxicam solid dispersion to enhance dissolution rate and solubility rate with the aid of novel polymers by adopting design of experiment CCD software technology. Nine SD formulations prepared with varying concentrations of PEG 4000, Labrasol, Soluplus, Kolliphor EL, Kolliwax GMS II, HPMC, Colloidal Silicone dioxide (Aerosil 200), and PVPK25 in three different drugs : polymer : surfactant (SLS) ratios of1:1:1,1:2:1 and 1:3:1 by solvent evaporation method and were evaluated for drug content,% practical yield and dissolution rate and solubility studies. The solubility study indicates that formulation (SD9) containing drug: Soluplus (1:3) and SLS has superior solubility of 0.68±0.10µg/ml, which is 75-fold higher than pure drug. The formulations SD9 maximum percentage yield and drug content. The optimized Lornoxicam solid dispersion (SD9) was further used to prepare FDT by direct compression method using 33 Response surface method (3variables and 3 levels of super disintegrants) by using Design of experiments of tware with super disintegrants like locust bean gum, gum karaya, plantago ovate and diluents such as mannitol, Avicel PH101 and aspartame as sweating agent and aerosol as anti adherent. Total 27 Lornoxicam FDTs formulated using natural super disintegrants locust bean gum, gum karaya, plantago ovate mucilage with varying concentrations by design of experiment tool. All the formulations evaluated for various parameters such as compatibility studies, drug content, weight variation, hardness, thickness, friability, disintegration time, in vitro drug release studies. The formulation LF24 showed highest drug release of 99.21±1.87 % at 10mins. LF24 was found to be optimized formulation which contains different concentrations of locust bean gum, gum karaya, plantago ovate mucilage the results were analysed by ANOVA and FTIR studies which shows no interaction between the ingredients. The % CDR of Lornoxicam FDT (LF24) was much higher than that of Lornoxicam marketed formulation. Thus, Lornoxicam FDTs using natural super disintegrants like locust bean gum, gum karaya, plantago ovate mucilage were suitable combinations for formulating Lornoxicam FDTs.

The aim of present work is to study the release of diltiazem hydrochloride from tablets with ethyl cellulose (EC), eudragit RSPO and kollidon SR in different drug-to-polymer ratios were investigated with a view to develop twice-daily sustained release dosage form by polymeric dispersion (PD) technique. The polymeric dispersions containing ehtyl cellulose, eudragit RSPO or kollidon SR at drug-polymer ratios of 1:0.5, 1:1, 1:1.5, 1:2, with diltiazem hydrochloride were developed using solvent evaporation technique and co precipitation technique. The physical mixtures of drug and polymers were prepared by using simple mixing technique at the same ratio. The study of FTIR could not show significant interaction between diltiazem HCl and ethyl cellulose or kollidon SR or eudragit RSPO. Prepared tablets were evaluated for the release of diltiazem Hydrochloride over a period of 12 h in pH 7.4 phosphate buffer using US Pharmacopoeia type II dissolution apparatus. The in vitro drug release study revealed that the tablets prepared by dispersion technique have extended the release rate for 12 h whereas the tablets prepared by physical mixing technique at the same concentration have extended the release rate only up to 8 h. The in vitro release profile and the mathematical models indicate that release of diltiazem Hydrochloride can be effectively controlled from a tablet containing polymeric dispersion of eudragit RSPO.